Jack Cuzick, PhD, FMedSci, FRCP(hon)
Director, Wolfson Institute of Preventive Medicine and
Head, Centre for Cancer Prevention
Centre for Cancer Prevention
Tel: +44 (0) 20 7882 3504
I am director of Wolfson Institute of Preventive Medicine in London and also head of Centre for Cancer Prevention, appointed as the John Snow Professor of Epidemiology at Queen Mary, University of London. I hold a PhD in Mathematics and have previously worked at Oxford University and Columbia University, New York.
My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. I am a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians.
In 2007, I was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. I was awarded the AACR Cancer Prevention Prize in 2012.
I am the author of more than 500 peer-reviewed papers and have published in all the major medical journals.
- Cancer epidemiology and clinical trials, with special interest in prevention and screening
I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.
I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.
I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.
- Recurrence in DCIS
- Predictors studies
- Biomarkers for breast DCIS progression
- Overview of SERM breast cancer prevention trials
- Molecular markers for prognosis of prostate cancer
- Role of low penetrance SNPs in risk assessment of breast cancer
- Technical evaluation of the Xpert assay in general screening population
- HPV vaccine studies
- HPV based screening
- Prostate Cancer Programme
- Breast cancer following benign breast disease
- Cancer after arsenic exposure
- Role of Aspririn in cancer prevention
- Risk predictions of colorectal cancer in individual with large adenomas
- Use of breast screening appointments to provide risk estimates and discuss preventive options
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
- Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial..
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study..
- Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.